Glucocorticoid-induced hyperglycemia

American Journal of the Medical Sciences

Volumn 345, Issue 4, 2013, Pages 274-277

  Kwon, Soonho ^a   Hermayer, Kathie L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Diabetes mellitus; Glucocorticoids; Hyperglycemia; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIINFLAMMATORY AGENT; DEXAMETHASONE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOCORTICOID; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PREDNISOLONE; PREDNISONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; BODY MASS; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIABETES MELLITUS; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GLUCOCORTICOID INDUCED HYPERGLYCEMIA; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INSULIN TREATMENT; KIDNEY TRANSPLANTATION; LACTIC ACIDOSIS; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PREVALENCE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 84876179859     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31828a6a01     Document Type: Conference Paper

References (36)

1. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 2006;29:2728-29.
2. Chan HW, Cheung CY, Liu YL, et al. Prevalence of abnormal glucose metabolism in Chinese renal transplant recipients: a single center study. Nephrol Dial Transplant 2008;23:3337-42.
3. Bonato V, Barni R, Cataldo D, et al. Analysis of posttransplant diabetes mellitus prevalence in a population of kidney transplant recipients. Transplant Proc 2008;40:1888-90.
4. Panthakalam S, Bhatnagar D, Klimink P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 2004;49:139-41.
5. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 2002;17:717-20.
6. Clore J, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009;15:469-74.
7. Donihi AC, Raval D, Saul M, et al. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract 2006;12:358-62.
8. Uzu T, Harada T, Sakaguchi M, et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal disease. Nephron Clin Pract 2007;105:c54-c75.
9. Strohmayer E, Krakoff L. Glucocorticoids and cardiovascular risk factors. Endocrinol Metab Clin North Am 2011;40:409-17.
10. Pagano G, Cavalloperin P, Cassader M, et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest 1983;72:1814-20.
11. Abdelmannan D, Tahboub R, Genuth S, et al. Effect of dexamethasone on oral glucose tolerance in normal individuals. Endocr Pract 2010;16:770-7.
12. Weinstein SP, Wilson CM, Pritsker A, et al. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism 1998;47:3-6.
13. Ruzzin J, Wagman AS, Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia 2005;48: 2119-30.
14. Buren J, Lai YC, Lundgren M, et al. Insulin action and signalling in fat and muscle from dexamethasone-treated rats. Arch Biochem Biophys 2008;474:91-101.
15. Henriksen JE, Alford F, Vaag A, et al. Intracellular skeletal muscle glucose metabolism is differentially altered by dexamethasone treatment of normoglycemic relatives of type 2 diabetic patients. Metabolism 1999;48:1128-35.
16. Ekstrand A, Schalin Jantti C, Lofman M, et al. The effect of (steroid) immunosuppression on skeletal muscle glycogen metabolism in patients after kidney transplantation. Transplantation 1996;61:889-93.
17. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose-production and stimulation of glucose utilization due to a postreceptor defect of insulin action. J Clin Endocrinol Metab 1982;54:131-8.
18. Dirlewanger M, Schneiter P, Paquot N, et al. Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clin Nutr 2000;19:29-34.
19. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-46.
20. Magee MH, Blum RA, Lates CD, et al. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol 2001;41:1180-94.
21. Gustavson SM, Sandoval DA, Ertl AC, et al. Stimulation of both type I and type II corticosteroid receptors blunts counterregulatory responses to subsequent hypoglycemia in healthy man. Am J Physiol Endocrinol Metab 2008;294:E506-12.
22. Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006;54:2765-75.
23. Muggeo M, Verlato G, Bonora E, et al. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation 1997;96:1750-54.
24. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57:1349-54.
25. Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am 1999;25:489-505.
26. Baldwin D Jr, Duffin KE. Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation 2004;77:1009-14.
27. Luther P, Baldwin D Jr. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 2004;4:2135-38.
28. Trence DL. Management of patients on chronic glucocorticoid therapy: an endocrine perspective. Prim Care 2003;30:593-605.
29. Holman RR, Thorne KI, Farmer AJ, et al; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30.
30. Campbell PJ, Gerich JE. Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for the adverse effect of obesity. J Clin Endocrinol Metab 1990;70:1114-18.
31. Hawkins K, Donihi AC, Korytkowaski MT. Glycemic management in medical and surgical patients in the non-ICU settings. Curr Diab Rep 2013;13:96-106.
32. Lansang M, Hustak L. Glucocorticoid-induced diabetes and adrenal suppression. Cleve Clin J Med 2011;78:748-56.
33. Davidson J, Wilkinson A, Dantal J, et al; International Expert Panel. New onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003;75(suppl 10): SS3-24.
34. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59.
35. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
36. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009;39:81-93.